The Fungal Pathogenesis & Drug Discovery Group investigates how fungal pathogens, such as Cryptococcus neoformans, cause disease, with a focus on discovering new antifungal drug targets. We explore critical metabolic pathways and virulence mechanisms to develop novel therapies for life-threatening fungal infections. Collaborations with international and Australian institutions support our translational research efforts, which bridge molecular biology, genetics, and drug discovery to tackle the global health challenge of invasive fungal diseases.
Recent Achievements
- Discovery of Key Virulence Mechanisms
Identified inositol polyphosphate biosynthesis pathways in Cryptococcus neoformans that are central to virulence, paving the way for targeted antifungal therapies. - Collaborative Drug Discovery Advances
Initiated successful collaborations with Sydney Analytical and Monash University, leading to a provisional patent for novel antifungal inhibitors. - Publication in High-Impact Journals
Published key findings on fungal kinase activities and metabolic pathways impacting virulence, contributing significantly to the field of fungal pathogenesis.
Recent publications
Arg1 from Cryptococcus neoformans and Fungal Virulence. mBio, 2024
June 2024
RTA1 in Cryptococcus neoformans and Fungal Protein Secretion, Pathogens, 2022
TNP Analogues Inhibiting Virulence Kinase Arg1 Biomolecules, 2022
Inositol Polyphosphate-Protein Interactions in Pathogenicity Cellular Microbiology, 2021
Metabolic Inflexibility in Cryptococcus neoformans Pathogens, 2020
Group Members
Name | Role |
Associate Professor Julie Djordjevic | Group Leader, Senior Researcher |
Desmarini Desmarini | Postdoctoral Fellow, Drug Discovery Research |
Pooja Sethiya | Postdoctoral Research Scientist |
Rana Baraz | Research Assistant |
Keren Francis | Senior Research Assistant |